Jeff Baxter Purchases 10,000 Shares of VBI Vaccines, Inc. (NASDAQ:VBIV) Stock
VBI Vaccines, Inc. (NASDAQ:VBIV) CEO Jeff Baxter acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were acquired at an average price of $3.28 per share, with a total value of $32,800.00. Following the acquisition, the chief executive officer now owns 110,255 shares in the company, valued at $361,636.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
VBI Vaccines, Inc. (NASDAQ VBIV) traded up 6.36% during trading on Monday, reaching $3.68. The company had a trading volume of 87,059 shares. The company’s 50-day moving average is $4.37 and its 200 day moving average is $4.61. The firm’s market capitalization is $148.04 million. VBI Vaccines, Inc. has a 52 week low of $2.75 and a 52 week high of $6.60.
Large investors have recently bought and sold shares of the company. Bank of Montreal Can boosted its stake in VBI Vaccines by 8.6% in the second quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 5,000 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in VBI Vaccines during the second quarter valued at about $187,000. Bank of New York Mellon Corp acquired a new stake in VBI Vaccines during the second quarter valued at about $193,000. Teachers Advisors LLC acquired a new stake in VBI Vaccines during the second quarter valued at about $195,000. Finally, TIAA CREF Investment Management LLC purchased a new position in VBI Vaccines during the second quarter valued at approximately $262,000. 29.49% of the stock is owned by institutional investors.
VBIV has been the subject of a number of recent analyst reports. Noble Financial restated a “buy” rating on shares of VBI Vaccines in a report on Friday, May 5th. Zacks Investment Research upgraded VBI Vaccines from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Saturday, May 6th. TheStreet cut VBI Vaccines from a “c-” rating to a “d+” rating in a report on Wednesday, May 31st. Finally, ValuEngine upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Two analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $5.38.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.